RNXT Stock Summary and Trading Ideas (Renovorx | NASDAQ:RNXT)

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Renovorx trades on the NASDAQ stock market under the symbol RNXT.

As of January 14, 2026, RNXT stock price climbed to $1.06 with 189,433 million shares trading.

RNXT has a beta of 0.82, meaning it tends to be less sensitive to market movements. RNXT has a correlation of 0.03 to the broad based SPY ETF.

RNXT has a market cap of $38.84 million. This is considered a Sub-Micro Cap stock.

Last quarter Renovorx reported $266,000 in Revenue and -$.08 earnings per share. This fell short of revenue expectation by $-80,400 and met earnings estimates .

In the last 3 years, RNXT traded as high as $5.75 and as low as $.53.

The top ETF exchange traded funds that RNXT belongs to (by Net Assets): VTI, VXF.

RNXT has underperformed the market in the last year with a return of -21.5%, while the SPY ETF gained +20.0%. In the last 3 month period, RNXT fell short of the market, returning -1.9%, while SPY returned +4.4%. However, in the most recent 2 weeks RNXT has outperformed the stock market by returning +21.2%, while SPY returned +0.5%.

RNXT support price is $.97 and resistance is $1.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNXT shares will trade within this expected range on the day.